A rare eye disease has been added to the growing list of side effects linked to GLP-1s, adding a second eye warning to several labels. Michael Siluk/UCG/Universal Images Group via Getty Images

The FDA is requiring new warnings on Ozempic, Wegovy, Mounjaro, Zepbound, and other GLP-1s about a potential increase in the risk of a rare eye condition that can cause sudden vision loss.

Regulators in the European Union, United Kingdom, and Australia have added similar warnings, mostly for semaglutide.

The FDA said the benefits of GLP-1 medications still outweigh their risks when used as directed.

GLP-1 users have a new symptom to watch for: Sudden vision loss in one eye.

The Food and Drug Administration (FDA) announced on November 9 that it will require drugmakers to add information to the warning labels of Ozempic, Wegovy, Mounjaro, Zepbound and other GLP-1 medications about “a potential increased risk” of a rare eye condition called nonarteritic anterior ischemic optic neuropathy (NAION).GLP-1 medications are approved to treat type 2 diabetes and to help people lose weight and keep it off.NAION joins a growing list of side effects linked to GLP-1s, adding a second eye warning to several labels.The U.S. labels for Ozempic, Rybelsus, Trulicity, Mounjaro, and Zepbound already warn about diabetic retinopathy, a diabetes-related eye disease, according to each drug’s prescribing information.The two conditions affect different parts of the eye. Diabetic retinopathy damages tiny blood vessels in the retina, the layer at the back of the eye that senses light, according to the National Eye Institute. NAION damages the optic nerve when it doesn’t get enough blood, according to the FDA’s announcement.Mihail Zilbermint, MD, director of endocrine hospitalists at Johns Hopkins, told Healthline he hasn’t seen NAION in his patients. He has seen vision worsen in some people after they start a GLP-1.“But we believe that’s probably related to rapid improvement in their sugar control, which can also be seen in someone who is starting insulin,” Zilbermint said.

Why the FDA added vision loss warning to Ozempic, other GLP-1s

A 2024 study published in JAMA Ophthalmology “initially triggered” the FDA’s review, the agency told Healthline.

The study found a higher risk of NAION in people prescribed semaglutide, the active ingredient in Ozempic and Wegovy, than in people prescribed other diabetes or weight-loss drugs.The authors wrote that more research is needed to determine whether semaglutide causes NAION.Joseph F. Rizzo III, MD, director of the Neuro-Ophthalmology Service at Mass Eye and Ear in Boston, served as the study’s corresponding author.

In a 2024 podcast, Rizzo said he and a resident saw three patients with NAION who were taking semaglutide for about a week.“And because NAION is a fairly uncommon disorder in the general population, the fact that we had three within a relatively short period of time led me to suspect that there was a higher risk of developing NAION in patients on semaglutide,” Rizzo said. The FDA analyzed clinical trials for multiple GLP-1 drugs and noted that NAION cases were reported with every GLP-1 on the market, according to its announcement. Those findings led the FDA to require the warning for the entire drug class, the agency told Healthline.

NAION symptoms: Signs of vision loss on Ozempic, Wegovy or Zepbound

About 70% to 80% of people with NAION first notice vision loss when they wake up, according to StatPearls. The FDA listed these symptoms:

sudden, painless vision loss in one eye

blind spots, tunnel vision, or other missing parts of vision

colors that look distorted

blurry or hazy spots in the center of vision

No treatment has been proven to reverse vision loss from NAION, according to StatPearls.

What to do if you notice vision loss while taking a GLP-1

“Patients experiencing sudden, painless vision loss in one eye should contact their healthcare professional immediately and should not stop their medication without consulting their provider first,” the FDA told Healthline.

In the announcement, the agency told doctors to promptly refer patients with suspected NAION to an ophthalmologist.

Who is more at risk for NAION?

The FDA listed these possible risk factors for NAION:

Habits: Smoking.

History: A past case of NAION in one eye raises the risk for the other eye.

Health conditions: These may include diabetes, high blood pressure, sleep apnea, kidney disease, and anemia.

The FDA told Healthline that many people who take GLP-1s also have these conditions, which made reports of NAION in GLP-1 users “challenging” to interpret.

How common is vision loss with GLP-1s?

Across 126 clinical trials, the FDA found about 6 NAION cases per 100,000 people taking a GLP-1 for a year, and about 4 per 100,000 people taking a placebo or another diabetes drug for a year.In real-world data, NAION was more common with GLP-1s than with one type of diabetes pill, but the FDA found no significant increase compared with another type, the agency told Healthline.Zilbermint said patients who saw the news have worried about losing their vision. He tells them that “many of the serious harms, including the potential harm of NAION, are rare.”“The overall risk is still very small,” he said.

Ozempic eye warnings in Europe, the U.K. and Australia

Regulators in other countries have added NAION warnings, mostly for semaglutide:

European Union: The European Medicines Agency added NAION to semaglutide’s product information as a “very rare” side effect in 2025.

United Kingdom: The Medicines and Healthcare products Regulatory Agency announced similar label updates in February 2026.

Australia: The Therapeutic Goods Administration added a NAION warning for semaglutide and listed NAION as a possible side effect of other GLP-1s.

What to do if you take a GLP-1

The FDA told Healthline the benefits of GLP-1s “continue to outweigh their risks when used as directed.”The FDA has also approved some GLP-1s to lower the risk of heart attack and stroke, reduce the risk of worsening kidney disease, and treat sleep apnea and a type of liver disease.Zilbermint said that “for most of my patients with obesity, diabetes and heart disease, the benefits clearly outweigh the risks.”“But we definitely have to decide patient by patient,” he added.

Which GLP-1 drugs get the new vision loss warning?

The labeling change applies to these medications, according to the FDA’s announcement:

Generic exenatide (formerly sold as Byetta)

Victoza and Saxenda (liraglutide)

Trulicity (dulaglutide)

Xultophy (liraglutide and insulin degludec)

Soliqua (lixisenatide and insulin glargine)

Ozempic, Rybelsus and Wegovy (semaglutide)

Mounjaro and Zepbound (tirzepatide)

Foundayo (orforglipron)

As of publication, the FDA’s online label database did not yet show the new warning on the drugs’ labels.

Novartis confirms that nine patients treated with its spinal muscular atrophy gene therapy Zolgensma have developed tumors; the FDA orders GLP-1 drugmakers to add a warning to their labels about the risk of a rare eye condition that can lead to vision loss; and the agency is set to decide on no fewer than 11 therapies this month, including closely watched applications from Summit Therapeutics, Vertex and Capricor Therapeutics.

(MedPage Today) — The oral GLP-1 receptor agonist orforglipron (Foundayo) improved sleep-disordered breathing in patients with moderate-to-severe obstructive sleep apnea and overweight or obesity, two phase III trials showed.
For the treatment…

Adults with moderate-to-severe sleep apnea and excess weight had significantly fewer episodes of breathing interruptions while sleeping after taking the daily oral GLP-1 medication orforglipron for one year, compared with adults in the placebo group, according to new, independent, preliminary late-breaking science presented Monday at the American Heart Association’s Scientific Sessions 2026 in Chicago.

A study has revealed that resistance (weight) training not only preserves lean and muscle mass but also increases strength in people taking weight-loss medication. Published in Nature Medicine, the Tirzepatide and Resistance Exercise (T-REx) study is the first to show the effects of combining a GLP-1 medicine and resistance training on body composition, muscle mass, strength and a range of cardiovascular health measures.

A former Eli Lilly sales rep filed a lawsuit alleging she was fired after claiming the company was inappropriately promoting its Mounjaro diabetes drug to combat weight loss.

The FDA warned that GLP-1 drugs carry a potential risk of a rare but serious eye condition sometimes referred to as an “eye stroke.”

The FDA approved a novel drug to reduce recurrence of stroke, the agency is warning that GLP-1s carry a potential risk for an eye condition, and more pharma news of…

Tuesday, November 11 – They’re the blockbuster drugs transforming weight loss, helping millions of people to shed unwanted kilograms. But while medications such as Ozempic and Wegovy may also improve women’s chances of becoming pregnant, what happens to their unborn babies if they continue to take the drugs during pregnancy?

Tuesday, November 11 – There’s a new alert on those popular GLP-1 weight loss drugs. The FDA is now mandating a warning label that the drugs may cause sudden blindness. NBC News’ Stephanie Gosk reports. 

Tuesday, November 11 – The Food and Drug Administration is adding a new warning about possible rare cases of vision loss reported with popular drugs used for weight loss and diabetes, such as Ozempic

Tuesday, November 11 – A former pharmaceutical sales representative on Monday told a Texas federal court that Eli Lilly and Co. wrongfully fired her after she blew the whistle on the company’s practice of offering its lucrative drug Mounjaro as a weight loss drug, saying Eli Lilly asked her to breach the law.

Tuesday, November 11 – Twelve marketed drugs, including Eli Lilly’s and Novo’s weight loss mega-blockbusters, will require a label change under the new FDA update.

Tuesday, November 11 – Years of research point to obesity and type 2 diabetes raising the risk of developing several types of cancer. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), a recent medical breakthrough, were originally developed for blood sugar control or diabetes management and also work overtime promoting weight loss. Scientists are curious to explore whether there are any links between these drugs and the onset of cancers in people with diabetes.

Tuesday, November 11 – GLP-1 drugs may increase the risk of NAION, a rare optic nerve condition that can lead to sudden vision loss. It has no known treatment.

Tuesday, November 11 – The U.S. Food and Drug Administration on Monday said it is requiring new warnings on GLP-1 medications, the group of blockbuster drugs prescribed for diabetes and weight loss, for a serious, rare condition that can cause sudden and possibly permanent vision loss in one eye.

Tuesday, November 11 – (MedPage Today) — The FDA is requiring manufacturers of all GLP-1 drugs to update their prescribing information to include a warning about the potential risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare but potentially blinding…

Tuesday, November 11 – A rare risk of vision loss and the potential for malignancies are on the U.S. FDA’s radar as it orders a new safety warning for GLP-1 drugs and investigates the risk of neoplasia with Novartis AG’s Zolgensma and Itvisma, both of which are onasemnogene abeparvovec products indicated for spinal muscular atrophy.

Tuesday, November 11 – The FDA on Monday warned that GLP-1 drugs carry a potential risk for a rare but serious eye condition that’s sometimes referred to as an “eye stroke.”

Tuesday, November 11 – Eli Lilly’s GLP-1 pill Foundayo helped alleviate sleep apnea in two late-stage studies, but it doesn’t appear as effective as Lilly’s injectable drug Zepbound.

Monday, November 9 – Gary Brecka says just six minutes of daily resistance training can help protect lean body mass during Ozempic and Wegovy weight loss journeys.

Monday, November 9 – (MedPage Today) — ORLANDO — The investigational obesity drug retatrutide was highly effective in reducing pain and improving disability in knee osteoarthritis (OA) associated with obesity, according to the TRIUMPH-4 trial.
Among patients in…

Sunday, November 8 – (MedPage Today) — A few clicks, a credit card, and a package arrives at your door. The same technology that has expanded access to information and consumer goods has also made it easier than ever for unregulated products to reach consumers while…

Saturday, November 7 – Bariatric surgery is associated with clinically meaningful two-year weight loss after semaglutide or tirzepatide intolerance or inadequate response, according to a study published online Nov. 3 in the Annals of Surgery.

Friday, November 6 – (MedPage Today) — Diabetic patients treated with GLP-1 receptor agonists had a lower cancer risk versus insulin and sulfonylureas but not other diabetes medications, although the benefits varied by diabetes severity, a large cohort analysis with…

Thursday, November 5 – With the first Phase 3 data expected for Amgen’s MariTide next year, analysts are looking for evidence that the GLP-1 candidate is tolerable. Meanwhile, the company has begun testing an autoinjector formulation.

Thursday, November 5 – A new tablet version of Wegovy, a peptide used to help people lose weight, has been approved for the first time in Australia.

Thursday, November 5 – Novo CEO Mike Maziar Doustdar insists that his company is ahead of fierce rival Eli Lilly as oral Wegovy rises to 8 million total prescriptions since its January launch.

Wednesday, November 4 – GLP-1 drugs like Ozempic and Mounjaro treated prediabetes more effectively than metformin, according to a new study. Milko/E+/Getty Images

Researchers say GLP-1 medications appear to be more effective in treating prediabetes than the commonly prescribed drug metformin.

They said GLP-1 drugs were also associated with a lower risk of developing type 2 diabetes as well as fewer cases of heart attack and stroke.

Stanford researchers have discovered an AI-identified natural molecule that dramatically suppresses appetite and promotes fat loss in animals, potentially offering an Ozempic-like weight-loss treatment without common digestive side effects or significant muscle loss. Called BRP, the molecule reduced food intake by up to 50% and targets a different brain pathway, raising hopes for a more precise obesity treatment if future human trials prove successful.

Tuesday, November 3 – (MedPage Today) — BALTIMORE — Use of a combined GLP-1/GIP receptor agonist was associated with improved menstrual regularity, an analysis of a prospective cohort showed.
Women taking the combination incretin drug had a reduction in cycle length…

Tuesday, November 3 – A compounding pharmacy deceptively and falsely marketed its GLP-1 compounded weight loss medications as safe, effective, clinically supported and personalized, according to a proposed class action filed in New Jersey federal court.

Tuesday, November 3 – GLP-1 (glucagon-like peptide-1 receptor agonists) medications, currently popular for weight loss, may help prevent type 2 diabetes and lower the risk of heart attack and stroke more than the standard diabetes prevention medication metformin among people with prediabetes, according to new, independent, preliminary research presented at the American Heart Association’s Scientific Sessions 2026, held Nov. 6–9 in Chicago.

Sunday, November 1 – (MedPage Today) — I am a South Asian physician — Pakistani, to be specific. By the American Diabetes Association’s (ADA) own rule, my doctor should begin screening me for diabetes once my body mass index (BMI) passes 23, because Asian Americans…

Saturday, October 31 – Experimental weight-loss drug retatrutide may help improve speep apnea.

Friday, October 30 – While many are aware of terms like “Ozempic face” and “Ozempic butt,” people are discovering another “side effect” of GLP-1 medications.View Entire Post ›

Friday, October 30 – “I still don’t see ‘me’ in the mirror.”View Entire Post ›

Friday, October 30 – With the commercial business performing so well, Eli Lilly is eyeing earlier business development bets to build out a longer-term pipeline.

Friday, October 30 – People who regain weight after bariatric surgery may benefit from glucagon-like peptide-1 receptor agonists, commonly called GLP-1 medications, according to a study involving Regenstrief Institute, Indiana University, Purdue University and University of Florida researchers. The study found that patients prescribed these medications lost more of their regained weight over six and 12 months than comparable patients who did not use them.

Friday, October 30 – Eli Lilly’s shares rose 4% in early morning trading after reporting revenue of $24.4 billion, well past consensus estimates.